Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13583780 | 0.74 | — | — | |
| SCHEMBL12581238 | 0.74 | ACLY (0.35) | L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL2866746 | 0.72 | CYP4F2 (0.34) | — | |
| SCHEMBL21340475 | 0.72 | TSHR (0.38) | L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL25315695 | 0.69 | GGT1 (0.37) | L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL24633725 | 0.69 | GGT1 (0.37) | L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL25315606 | 0.69 | GGT1 (0.37) | L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL1892027 | 0.69 | MEN1 (0.46) | L3MBTL1MEN1POLBKMT2A | |
| Pivalate SCHEMBL9055894 | 0.69 | TDP1 (0.35) | L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL4447829 | 0.68 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | DCTD, DDC, DAO | L3MBTL1 1481/4885MEN1 2339/4885POLB 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.